Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting

April 9, 2024

https://www.globenewswire.com/news-release/2024/04/09/2860242/0/en/Compass-Therapeutics-Presents-Data-Demonstrating-Elimination-of-MHC-Class-I-Negative-Tumors-in-In-Vivo-Models-at-the-2024-American-Association-for-Cancer-Research-AACR-Annual-Meeti.html

BOSTON, April 09, 2024 (GLOBE NEWSWIRE) — Compass Therapeutics, Inc. (Nasdaq:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today presents a poster on the combination of its bispecific antibody, CTX-009, and its agonistic anti-CD137 antibody, CTX-471, on anti-tumor activity in preclinical models at the 2024 American Association for Cancer Research (AACR) Annual Meeting taking place at the San Diego Convention Center in San Diego, California on April 9.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.